(Q41758819)

8 October 2017

title

Medical treatment: does it influence the natural course of inflammatory bowel disease? (English)

1 reference

inflammatory bowel diseases

8 October 2017

main subject

0 references

1

Moum B

1 reference

8 October 2017

publication date

1 August 2000

1 reference

European Journal of Internal Medicine

8 October 2017

published in

1 reference

8 October 2017

volume

11

1 reference

8 October 2017

issue

4

1 reference

8 October 2017

page(s)

197-203

1 reference

THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Course and prognosis of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Maintenance therapy for inflammatory bowel disease: what really works

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Crohn's disease and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Management of inflammatory bowel disease: 30 years of observation

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Commonalities in the time trends of Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Prognosis in ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Survival and causes of death in patients with inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Inflammatory bowel disease in northern Alberta. An epidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Oral BCG vaccine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Disodium cromoglycate in the treatment of ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Total parenteral nutrition as the sole therapy in Crohn's disease--a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Disease activity courses in a regional cohort of Crohn's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

The course of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Prognosis of chronic ulcerative colitis in a community

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Clinical patterns, natural history, and progression of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Diffuse jejunoileitis of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Surgical management of Crohn's disease. Influence of disease at margin of resection

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Colorectal cancer risk and mortality in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Assessment of severity in colitis: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Maintenance therapy in ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Changes in extent of ulcerative colitis: a study on the course and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Microscopic activity in ulcerative colitis: what does it mean?

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Incidence of Crohn's Disease in Four Counties in Southeastern Norway, 1990–93 A Prospective Population-Based Study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

A meta-analysis of the role of smoking in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Smoking habits and recurrence in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Smoking, the oral contraceptive pill, and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Seasonal variations in the onset of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Why do patients with ulcerative colitis relapse?

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Factors inducing relapse in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Analgesic ingestion and other factors preceding relapse in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Do life events or depression exacerbate inflammatory bowel disease? A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Perinatal risk factors for inflammatory bowel disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Quantification of the placebo response in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

Complementary medicine use by patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900091-1

7 January 2021

10.1016/S0953-6205(00)00091-1

Identifiers

DOI

1 reference

8 October 2017

1 reference